Pancreatic Cancer Research

ResearcherNagoya City UniversityActive in the last 2 years

Kenta Saito

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3590-2189; OpenAlex author ID A5101507907. Sources: OpenAlex.

Their work

Papers
14
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 3 papers · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 14

  1. Interleukin-1 receptor type 1 in pancreatic cancer progression and metastasis: a review. Co-author DOI 10.1007/s10147-026-03000-7↗
  2. The Natural Compound CalebinA Suppresses Gemcitabine Resistance and Tumor Progression by Inhibiting Angiogenesis and Invasion Through NF-κB Signaling in Pancre… Co-author DOI 10.3390/nu17162641↗
  3. Expression of ZKSCAN3 protein suppresses proliferation, migration, and invasion of pancreatic cancer through autophagy. Co-author DOI 10.1111/cas.16173↗
  4. The Natural Product Parthenolide Inhibits Both Angiogenesis and Invasiveness and Improves Gemcitabine Resistance by Suppressing Nuclear Factor κB Activation in… Co-author DOI 10.3390/nu16050705↗
  5. Concomitant Pancreatic Ductal Adenocarcinoma and Type 1 Autoimmune Pancreatitis: A Potential Issue in the Diagnosis of Carcinoma by Endoscopic Ultrasound-guide… Co-author DOI 10.2169/internalmedicine.0075-22↗
  6. Upregulation of integrin‑linked kinase enhances tumor progression in gemcitabine‑resistant pancreatic cancer. Co-author DOI 10.3892/or.2023.8601↗
  7. Girdin regulates both migration and angiogenesis in pancreatic cancer cell lines. Co-author DOI 10.3892/or.2023.8606↗
  8. 10Z‑Hymenialdisine inhibits angiogenesis by suppressing NF‑κB activation in pancreatic cancer cell lines. Co-author DOI 10.3892/or.2022.8259↗
  9. Enhanced CXCL12/CXCR4 signaling increases tumor progression in radiation‑resistant pancreatic cancer. Co-author DOI 10.3892/or.2022.8279↗
  10. Escin inhibits angiogenesis by suppressing interleukin‑8 and vascular endothelial growth factor production by blocking nuclear factor‑κB activation in pancreat… Co-author DOI 10.3892/or.2021.8006↗
  11. Acquisition of gemcitabine resistance enhances angiogenesis via upregulation of IL‑8 production in pancreatic cancer. Co-author DOI 10.3892/or.2019.7105↗
  12. [A Case of Conversion Surgery for an Initially Locally Advanced Unresectable Pancreatic Cancer after S-1 Chemotherapy]. Co-author PMID 32156996↗
  13. Xanthohumol inhibits angiogenesis by suppressing nuclear factor-κB activation in pancreatic cancer. Co-author DOI 10.1111/cas.13441↗
  14. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists. Co-author DOI 10.1186/s12885-016-2340-z↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoichi Matsuo · 14 shared papers, 2016–2026 · strength 1.98
  2. Shuji Takiguchi · 12 shared papers, 2018–2026 · strength 1.77
  3. Hiroki Takahashi · 12 shared papers, 2016–2025 · strength 1.55
  4. Tomokatsu Kato · 9 shared papers, 2021–2026 · strength 1.53
  5. Hiromichi Murase · 8 shared papers, 2022–2026 · strength 1.41
  6. Mamoru Morimoto · 11 shared papers, 2016–2024 · strength 1.34
  7. Hiroyuki Imafuji · 10 shared papers, 2018–2024 · strength 1.29
  8. Keisuke Nonoyama · 6 shared papers, 2023–2026 · strength 1.14
  9. Yuki Denda · 6 shared papers, 2023–2026 · strength 1.14
  10. Yuichi Hayashi · 7 shared papers, 2019–2023 · strength 0.85
  11. Kan Omi · 6 shared papers, 2019–2023 · strength 0.70
  12. Goro Ueda · 6 shared papers, 2019–2023 · strength 0.70
  13. Saburo Sugita · 3 shared papers, 2024–2025 · strength 0.57
  14. Yuki Eguchi · 3 shared papers, 2024–2025 · strength 0.57
  15. Kenji Notohara · 1 shared paper, 2023 · strength 0.15
  16. Kenta Kachi · 1 shared paper, 2023 · strength 0.15
  17. Itaru Naitoh · 1 shared paper, 2023 · strength 0.15
  18. Hiromi Kataoka · 1 shared paper, 2023 · strength 0.15
  19. Yasuki Hori · 1 shared paper, 2023 · strength 0.15
  20. Michihiro Yoshida · 1 shared paper, 2023 · strength 0.15
  21. Akihisa Kato · 1 shared paper, 2023 · strength 0.15
  22. Satoru Takahashi · 1 shared paper, 2023 · strength 0.15
  23. Tomoya Shamoto · 2 shared papers, 2016–2018 · strength 0.13
  24. Hiromitsu Takeyama · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.